Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The purpose of the study is to use 3D imaging to evaluate the effects of four FDA approved neuromodulators on facial lines, wrinkles and animation. Participation is available to women who have never had a cosmetic procedure above the malar region nor a treatment with a neuromodulator within 12 months. All subjects will undergo 3D imaging using the VECTRA M3 (Canfield Scientific, Inc, Fairfield, NJ) prior to treatment with a neuromodulator in order to determine their baseline dimensions. Imaging will be repeated post injection to determine change over time.
Epistemonikos ID: 33c06a011286a4499bc8de02b2d6a556f4d0c63f
First added on: May 09, 2024